Your session is about to expire
← Back to Search
Antibiotic
AEMCOLO (Rifamycin SV MMX) for Gastrointestinal Disease
Phase 2
Waitlist Available
Research Sponsored by Bradley Connor
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month after treatment
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new antibiotic called AEMCOLO to see if it can help people with Small Intestinal Bacterial Overgrowth (SIBO). AEMCOLO aims to reduce the excessive bacteria in the small intestine, which can cause digestive problems. The study will determine the most effective dose.
Eligible Conditions
- Small Intestinal Bacterial Overgrowth
- Gastroenteritis
- Gastrointestinal Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month after treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month after treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To assess the change of an abnormal breath test followed by a regimen of AEMCOLO
Secondary study objectives
To evaluate the change in clinical symptoms followed by a regimen of AEMCOLO
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: 2nd regimenExperimental Treatment1 Intervention
15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg tablets to take two tablets three times daily for 14 days (84 Tablets).
Group II: 1st regimenExperimental Treatment1 Intervention
15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg two tablets to take twice daily for 14 days (56 Tablets)
Find a Location
Who is running the clinical trial?
Bradley ConnorLead Sponsor
Share this study with friends
Copy Link
Messenger